TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02729857

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SFA muffin
Description: Muffin rich in saturated fat.
Study: NCT02736318

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OD-PHOENIX
Description: Decellularized, freeze-dried, irradiated osteochondral allograft
Study: NCT02729857

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: SFA muffin
Description: Muffin rich in saturated fat.
Study: NCT01749189

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blend
Description: 22 grams of protein/day
Study: NCT02729857

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PUFA muffin
Description: Muffin rich in polyunsaturated fat.
Study: NCT01749189

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey
Description: 22 grams of protein/day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 22 grams of carbohydrate/day
Study: NCT02729857

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: PUFA muffin
Description: Muffin rich in polyunsaturated fat.
Study: NCT04044001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTZ-043
Description: BTZ-043 (250mg per tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTZ-043
Description: BTZ-043 (250mg per tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTZ-043
Description: BTZ-043 (250mg per tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTZ-043
Description: BTZ-043 (250mg per tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTZ-043
Description: BTZ-043 (250mg per tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTZ-043
Description: BTZ-043 (250mg per tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTZ-043
Description: BTZ-043 (250mg per tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTZ-043
Description: BTZ-043 (250mg per tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTZ-043
Description: BTZ-043 (250mg per tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTZ-043
Description: BTZ-043 (250mg per tablet)
Study: NCT02022553

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: usual rectal cancer surgery
Study: NCT03448237

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Speech Therapy
Description: Speech therapy adapted to the child, at least 25 sessions over 9 months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive treatment
Description: Proprioceptive treatment adapted to the child.~This treatment aims to stabilize a central reference instability revealed to Maddox Postural by the use of neurosensory decoys::~* Proprioceptive stimulation of oculomotor muscles (active prisms).~* Oral somatosensory stimulation (ALPH).~* Proprioceptive antigravity stimulation (proprioceptive sole).~* Proprioceptive reprogramming exercise.~Following the teaching of the University Diploma: Perception-Action, Learning Disorders (University of Bourgogne, France)
Study: NCT02250352

Intervention type: OTHER
Intervention: cytology specimen collection procedure
Description: Correlative studies

Intervention type: OTHER
Intervention: cytology specimen collection procedure
Description: Correlative studies
Study: NCT04044001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTZ-043
Description: BTZ-043 (250mg per tablet)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifafour e-275®
Description: Rifafour e-275® (150mg rifampicin, 75mg isoniazid, 400mg pyrazinamide, 275 mg ethambutol per tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probe Drug Cocktail
Description: A probe drug cocktail will be given to randomly selected patients after inclusion on Day 1 and on Day 14 once orally. The probe drug cocktail consists of~* Caffeine: 1 tablet à 150mg~* Tolbutamide: 1/4 tablet à 500mg~* Dextromethorphan: 10 ml syrup à 15mg/5ml~* Midazolam:2 ml solution à 5mg/5ml~* Digoxin: 2 tablets à 0.25mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probe Drug Cocktail
Description: A probe drug cocktail will be given to randomly selected patients after inclusion on Day 1 and on Day 14 once orally. The probe drug cocktail consists of~* Caffeine: 1 tablet à 150mg~* Tolbutamide: 1/4 tablet à 500mg~* Dextromethorphan: 10 ml syrup à 15mg/5ml~* Midazolam:2 ml solution à 5mg/5ml~* Digoxin: 2 tablets à 0.25mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probe Drug Cocktail
Description: A probe drug cocktail will be given to randomly selected patients after inclusion on Day 1 and on Day 14 once orally. The probe drug cocktail consists of~* Caffeine: 1 tablet à 150mg~* Tolbutamide: 1/4 tablet à 500mg~* Dextromethorphan: 10 ml syrup à 15mg/5ml~* Midazolam:2 ml solution à 5mg/5ml~* Digoxin: 2 tablets à 0.25mg
Study: NCT04044001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50mg Tab
Description: 1 tablet à 50mg Dolutegravir will be given to randomly selected patients after inclusion on Day 1 and on Day 14 once orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50mg Tab
Description: 1 tablet à 50mg Dolutegravir will be given to randomly selected patients after inclusion on Day 1 and on Day 14 once orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50mg Tab
Description: 1 tablet à 50mg Dolutegravir will be given to randomly selected patients after inclusion on Day 1 and on Day 14 once orally.
Study: NCT03859297

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rumination-Focused CBT
Description: RF-CBT targets rumination and other maladaptive forms of emotion regulation such as suppression and avoidance and provides skills training in effectively coping with rumination. RF-CBT specifically targets rumination through psychoeducation, adopting a functional analytic approach to the learned habitual behavior of rumination, and a focus on shifting process style. The adolescent is taught to notice triggers to ruminate as well as the consequences of rumination and to shift into practicing a more adaptive strategy such as an attention training exercise, behavioral activation, thinking in a concrete way, or active problem-solving. RF-CBT directly teaches adolescents to recognize rumination or when the participant gets stuck in their head and to notice the influence this has on their mood.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation-based Therapy
Description: Sessions will include progressive muscle relaxation, simple breathing techniques, and guided imagery that focus on bodily and somatic relaxation. Adolescents randomized to Relaxation Therapy (RelaxT) will also receive exercises to do as homework in between sessions, parallel to the RF-CBT group.
Study: NCT04686721

Intervention type: DIAGNOSTIC_TEST
Intervention: Chest CT scan + baseline spirometry
Description: Patients will perform an initial evaluation at 2 months from hospital discharge using a chest CT scan without contrast-enhancing along with a pulmonary function test using spirometry. Based on results and according to current guidelines, further follow-up or intervention will be administered.
Study: NCT02022553

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RACHEL
Study: NCT03734913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1602
Description: ZSP1602 capsules for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1602
Description: ZSP1602 capsules for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1602
Description: ZSP1602 capsules for oral administration
Study: NCT02440841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fedovapagon

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fedovapagon

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifampicin
Study: NCT02403440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hetrombopag Olamine
Description: Hetrombopag Olamine 2.5mg, 5mg and 7.5mg
Study: NCT02504216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: 2.5 mg, twice daily, orally, tablet
Study: NCT06371391

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT02504216

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rivaroxaban-Placebo
Description: matching placebo, twice daily, orally, tablet
Study: NCT03667092

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: non-drug intervention type
Description: 8 peripheral blood samples (8x5ml) will be obtained at different times ; before, during and after treatment
Study: NCT03643068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KSP-QRH-E3-IRDye800 (Peptide 919288G), 0.6 mg
Description: The investigational agent to be used in this study is KSP/QRH dimer: a fluorescently-labeled peptide dimer composed of a 14-amino acid sequence \[Lys-Ser-Pro-Asn-Pro-Arg-Phe\] and \[Gln-Arg-His-Lys-Pro-Arg-Glu\] attached via a PEG3, Lys and Cys linker \[PEG3\]2-Lys-Cys to a near-infrared fluorophore, IRDye800CW (0.6 mg dose).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KSP-QRH-E3-IRDye800 (Peptide 919288G), 1.8 mg
Description: The investigational agent to be used in this study is KSP/QRH dimer: a fluorescently-labeled peptide dimer composed of a 14-amino acid sequence \[Lys-Ser-Pro-Asn-Pro-Arg-Phe\] and \[Gln-Arg-His-Lys-Pro-Arg-Glu\] attached via a PEG3, Lys and Cys linker \[PEG3\]2-Lys-Cys to a near-infrared fluorophore, IRDye800CW (1.8 mg dose).
Study: NCT06371391

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT02079103

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: During a 4 weeks period the patients will be offered 4-5 Virtual reality training sessions weekly of 45-60 minutes duration in addition to other rehabilitation. The Virtual reality training will be supervised by a physical or an occupational therapist. Virtual reality gaming parameters are adapted according to improving arm motor function.
Study: NCT02079103

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional arm training
Description: During a 4 weeks period the patients will be offered 4-5 supervised self-training sessions weekly of 45-60 minutes duration in addition to other rehabilitation. The training will be task-related and supervised by a physical or an occupational therapist. Exercises increase in difficulty according to improving arm motor function.
Study: NCT01326546

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Therapeutic HBV vaccine
Description: Inject εPA-44 900μg at week 0, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32, 36, 40, 44, 48.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entecavir
Description: 0.5mg,per day,oral intake.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: entecavir
Description: 0.5mg,per day,oral intake.
Study: NCT01625741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 2000 mg, IV, monthly, for 4 months (= 4 doses)
Study: NCT01851603

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AVL-3288
Description: Drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical diluent to that used for AVL-3288
Study: NCT03455231

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short course radiotherapy
Description: An accelerated hypo-fractionation radiotherapy is delivered for palliation in patients with complicated bone metastases
Study: NCT03173001

Intervention type: DIAGNOSTIC_TEST
Intervention: Parasitological examination
Description: Three stool samples for parasitological examination will be taken from control subjects and CRC patients at 1-2 days interval.

Intervention type: DIAGNOSTIC_TEST
Intervention: Parasitological examination
Description: Three stool samples for parasitological examination will be taken from control subjects and CRC patients at 1-2 days interval.

Intervention type: DIAGNOSTIC_TEST
Intervention: Parasitological examination
Description: Three stool samples for parasitological examination will be taken from control subjects and CRC patients at 1-2 days interval.
Study: NCT00737048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol Hydrochloride
Description: Tramadol hydrochloride two oral capsules will be administered once as 75 milligram (mg).
Study: NCT01326546

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Inject placebo 900μg at week 0, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32, 36, 40, 44, 48.
Study: NCT03173001

Intervention type: DIAGNOSTIC_TEST
Intervention: Parasitological examination
Description: Three stool samples for parasitological examination will be taken from control subjects and CRC patients at 1-2 days interval.
Study: NCT04081350

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LY3471851
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LY3471851
Description: Administered SC
Study: NCT00737048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen two oral capsules will be administered once as 650 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Two oral tablets or capsules of matching Placebo will be administered once along with Tramadol Hydrochloride and/or acetaminophen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Two oral tablets or capsules of matching Placebo will be administered once along with Tramadol Hydrochloride and/or acetaminophen.
Study: NCT04081350

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LY3471851
Description: Administered SC
Study: NCT00737048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Two oral tablets or capsules of matching Placebo will be administered once along with Tramadol Hydrochloride and/or acetaminophen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol plus Acetaminophen
Description: Tramadol hydrochloride and acetaminophen combination tablet will be administered as single oral dosing of two tablets at a dose of 75 and 650 milligram respectively.
Study: NCT03103958

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: Probiatop is a live microbial preparation saches containing 1g of the formulation composed by Lactobacillus acidophilus NCFM, 10⁹, Lactobacillus rhamnosus HN001 10⁹, Lactobacillus paracasei LPC-37 10⁹, Bifidobacterium lactis HN019 10⁹ combined with Polydextrose.~Subjects will take two sachets per day after diluting them in 100 ml of water

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo sachets were prepared by substituting equivalent amounts of Maltodextrin for the probiotic powder.~Subjects will take two sachets per day after diluting them in 100 ml of water
Study: NCT00478621

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' HPV vaccine (GSK1674330A)
Description: Intramuscular administration, 5 different formulations
Study: NCT03173001

Intervention type: DIAGNOSTIC_TEST
Intervention: Parasitological examination
Description: Three stool samples for parasitological examination will be taken from control subjects and CRC patients at 1-2 days interval.

Intervention type: DIAGNOSTIC_TEST
Intervention: Parasitological examination
Description: Three stool samples for parasitological examination will be taken from control subjects and CRC patients at 1-2 days interval.

Intervention type: DIAGNOSTIC_TEST
Intervention: Parasitological examination
Description: Three stool samples for parasitological examination will be taken from control subjects and CRC patients at 1-2 days interval.

Intervention type: DIAGNOSTIC_TEST
Intervention: Parasitological examination
Description: Three stool samples for parasitological examination will be taken from control subjects and CRC patients at 1-2 days interval.
Study: NCT00478621

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' HPV vaccine (GSK1674330A)
Description: Intramuscular administration, 5 different formulations

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' HPV vaccine (GSK1674330A)
Description: Intramuscular administration, 5 different formulations

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' HPV vaccine (GSK1674330A)
Description: Intramuscular administration, 5 different formulations

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' HPV vaccine (GSK1674330A)
Description: Intramuscular administration, 5 different formulations

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cervarix TM
Description: Intramuscular administration
Study: NCT03667521

Intervention type: PROCEDURE
Intervention: nerve-sparing laparaoscopic sacrocolpopexy
Description: nerve-sparing laparaoscopic sacrocolpopexy implemented after 2010
Study: NCT01467752

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MCP joint
Description: reconstruction of metacarpophalangeal (MCP) joint using a bone graft
Study: NCT01242319

Intervention type: BEHAVIORAL
Intervention: HeartAge intervention
Description: Computerized kiosk in waiting room with HeartAge risk calculator, PDA based decision support tool regarding hyperlipidemia management, website and tool box with coronary risk reduction tools for smoking cessation, diet and exercise, medication adherence
Study: NCT01147796

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: computed tomography
Description: 64 slices CT with iodine injection
Study: NCT01518270

Intervention type: OTHER
Intervention: No treatment
Description: No treatment will be provided
Study: NCT02578758

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transdiagnostic internet-based protocol
Description: Transdiagnostic internet-based protocol is an Internet-based Protocol for ED, which will allow the individual to learn and practice adaptive ways to regulate their emotions from a transdiagnostic perspective. The protocol contains the following components: present-focused emotional awareness, cognitive flexibility, emotional avoidance and emotion-driven behaviors, interoceptive and situation-based emotion exposure, psychoeducation about emotions, motivational enhancement and relapse prevention, which are organized in 12 modules: Emotional disorders and emotion regulation; Motivation for change; Understanding the role of emotions; The acceptance of emotional experiences; Practicing the acceptance; Learning to be flexible; Practicing the cognitive flexibility; The emotional avoidance; Emotion driven behaviors; Accepting and facing physical sensations; Facing emotions in the contexts in which they occur; and Relapse Prevention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transdiagnostic internet-based protocol + positive affect component
Description: Transdiagnostic internet-based protocol + positive affect component is an Internet-based protocol for ED. This protocol contains several transdiagnostic components (present-focused emotional awareness, cognitive flexibility, emotional avoidance and emotion-driven behaviors, interoceptive and situation-based emotion exposure, psychoeducation about emotions, motivational enhancement and relapse prevention) and a specific positive affect regulation component. These components are organized in 16 treatment modules: Emotional disorders and emotion regulation; Motivation for change; Understanding the role of emotions; The acceptance of emotional experiences; Practicing the acceptance; Learning to be flexible; Practicing the cognitive flexibility; The emotional avoidance; Emotion driven behaviors; Accepting and facing physical sensations; Facing emotions in the contexts in which they occur; Learning to move on; Learning to enjoy; Learning to live; Living and learning; and Relapse Prevention.
Study: NCT01147796

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: computed tomography
Description: 64 slices CT with iodine injection
Study: NCT01549574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crizotinib
Description: Each subject in Treatment A will receive a 250 mg single oral dose of crizotinib administered in a fasted state as 1x 250 mg Formulated Capsule on Day 1 and each subject in Treatment B will receive a 250 mg single oral dose of crizotinib administered in a fasted state as 1x 250 mg Formulated Capsule on Day 5
Study: NCT04081350

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT03152019

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Protopic® (Tacrolimus) 0.1% ointment
Description: About 0,1g of ointment is administered by the patient on nasal mucosa of each nostril twice a day for 6 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: About 0,1g of ointment is administered by the patient on nasal mucosa of each nostril twice a day for 6 weeks.
Study: NCT01647971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ublituximab
Description: Ublituximab is a novel monoclonal antibody targeting cluster of differentiate 20 (CD20)
Study: NCT01549574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esomeprazole
Description: Each subject in Treatment B will receive 40 mg daily dose of esomeprazole from Day 1 to Day 5
Study: NCT03112538

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Pump
Description: Medtronic Minimed Paradigm Veo Insulin Pump

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Pump
Description: Medtronic Minimed Paradigm Veo Insulin Pump

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Multiple daily injections of insulin
Description: Multiple daily injections which consist of a single injection of basal insulin(insulin Glargine) and 3 injections of bolus insulin(rapid acting insulin Glulisine or Aspart) before each meal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Multiple daily injections of insulin
Description: Multiple daily injections which consist of a single injection of basal insulin(insulin Glargine) and 3 injections of bolus insulin(rapid acting insulin Glulisine or Aspart) before each meal
Study: NCT02480296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MYK-461

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study: NCT02578758

Intervention type: OTHER
Group type: OTHER
Intervention: Waiting List Control Group
Description: Participants in a 18-week waiting list control condition. They will be offered the possibility of receiving the online treatment protocol after the wating list period.